Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer

Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer Cancer cells continue to challenge scientists and oncologists due to the phenomenon of resistance. Moreover, recurrence, as seen in many treated patients, shows that currently-used anti-cancer drugs are unable to prevent the development of new cancer cells harboring new mutations. The purpose of this paper is to try to answer some of the questions regarding why cancer arises and why evolution would naturally lead to the development of cancer. Providing answers to these questions may shed new light on cancer development and potential causes of cancer. This work demonstrates that (1) cancer hallmarks are a series of events that can be organized in three consecutive stages; (2) cancer may develop when cells seek immortality; (3) heterogeneity in tumors may be explained by cancer cells not following universal laws for division; (4) evolution may not have selected for cancer; (5) currently-used anti-cancer drugs, with telomerase and poly adenosine diphosphate ribose polymerase inhibition given as examples, show that we may not be on the right track, as these drugs are probably targeting molecular symptoms of tumors but not their cause; and (6) after an attempt to define the cause of cancer, the potentials of immunotherapy are discussed. Future anti-cancer drugs should be able to shrink the original tumor(s) and most importantly prevent the rise of new cancer cells in treated patients. In order to achieve this goal, new drugs must target the cause of cancer. Therefore, future research must focus on identifying potential causes of cancer common to all types of cancers. Finally, while immunotherapy holds great prospects for future cancer cure and prevention, global action is needed to reduce harmful substances known to contribute to the development of cancer in the environment. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer

Adjiri, Adouda
Oncology and Therapy , Volume 4 (1) – Jan 20, 2016
Download PDF
17 pages

Loading next page...
 
/lp/springer-journals/identifying-and-targeting-the-cause-of-cancer-is-needed-to-cure-cancer-N1xzB18JiM
Publisher
Springer Journals
Copyright
Copyright © 2016 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-015-0015-6
Publisher site
See Article on Publisher Site

Abstract

Cancer cells continue to challenge scientists and oncologists due to the phenomenon of resistance. Moreover, recurrence, as seen in many treated patients, shows that currently-used anti-cancer drugs are unable to prevent the development of new cancer cells harboring new mutations. The purpose of this paper is to try to answer some of the questions regarding why cancer arises and why evolution would naturally lead to the development of cancer. Providing answers to these questions may shed new light on cancer development and potential causes of cancer. This work demonstrates that (1) cancer hallmarks are a series of events that can be organized in three consecutive stages; (2) cancer may develop when cells seek immortality; (3) heterogeneity in tumors may be explained by cancer cells not following universal laws for division; (4) evolution may not have selected for cancer; (5) currently-used anti-cancer drugs, with telomerase and poly adenosine diphosphate ribose polymerase inhibition given as examples, show that we may not be on the right track, as these drugs are probably targeting molecular symptoms of tumors but not their cause; and (6) after an attempt to define the cause of cancer, the potentials of immunotherapy are discussed. Future anti-cancer drugs should be able to shrink the original tumor(s) and most importantly prevent the rise of new cancer cells in treated patients. In order to achieve this goal, new drugs must target the cause of cancer. Therefore, future research must focus on identifying potential causes of cancer common to all types of cancers. Finally, while immunotherapy holds great prospects for future cancer cure and prevention, global action is needed to reduce harmful substances known to contribute to the development of cancer in the environment.

Journal

Oncology and Therapy – Springer Journals

Published: Jan 20, 2016

References

  • Repopulation of cancer cells during therapy: an important cause of treatment failure
    Kim, JJ; Tannock, IF
  • Radiation oncology: a century of achievements
    Bernier, J; Hall, EJ; Giaccia, A
  • How can we overcome tumor hypoxia in radiation therapy?
    Harada, H
  • Radiation-induced genomic instability and its implications for radiation carcinogenesis
    Huang, L; Snyder, AR; Morgan, WF
  • Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glio-blastoma
    Wild-Bode, C; Weller, M; Rimner, A; Dichgans, J; Wick, W
  • Current status and new developments in ion therapy
    Karger, CP; Jäkel, O
  • Biomarkers for personalized oncology: recent advances and future challenges
    Kalia, M
  • Temozolomide in combination with carbon ion or photon irradiation in glioblastoma multiforme cell lines—does scheduling matter?
    Harrabi, S; Combs, SE; Brons, S; Haberer, T; Debus, J; Weber, KJ
  • Combining radiotherapy and cancer immunotherapy: a paradigm shift
    Formenti, SC; Demaria, S
  • Cancer genes and the pathways they control
    Vogelstein, B; Kinzler, KW
  • Neoplastic development,
    Foulds, L
  • Host factors in human carcinogenesis (IARC Scientific Publications No. 39)
    Weinstein, IB
  • Only three driver gene mutations are required for the development of lung and colorectal cancers
    Tomasetti, C; Marchionni, L; Nowak, MA; Parmigiani, G; Vogelstein, B
  • Hallmarks of cancer: the next generation
    Hanahan, D; Weinberg, RA
  • Noncanonical functions of telomerase: implications in telomerase-targeted cancer therapies
    Li, Yinghui; Tergaonkar, Vinay
  • Molecular imaging of cancer with positron emission tomography
    Gambhir, SS
  • Links between metabolism and cancer
    Dang, CV
  • Anti-angiogenic therapy for cancer: an update
    Al-Husein, B; Abdalla, M; Trepte, M; DeRemer, DL; Somanath, PR
  • Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
    Colotta, F; Allavena, P; Sica, A; Garlanda, C; Mantovani, A
  • Inflammation and lung carcinogenesis: applying findings in prevention and treatment
    Peebles, KA; Lee, JM; Mao, JT
  • Replicative senescence: implications for in vivo aging and tumor suppression
    Smith, JR; Pereira-Smith, OM
  • Cellular senescence: when bad things happen to good cells
    Campisi, J; di Fagagna, FA
  • Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
    Campisi, J
  • The essence of senescence
    Kuilman, T; Michaloglou, C; Mooi, WJ; Peeper, DS
  • CDK inhibitors: positive and negative regulators of G1-phase progression
    Sherr, CJ; Roberts, JM
  • Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all
    Gil, J; Peters, G
  • Human melanocyte senescence and melanoma susceptibility genes
    Bennett, DC
  • The p16INK4a/CDKN2A tumor suppressor and its relatives
    Ruas, M; Peters, G
  • Expression of CDK7/CAK in normal and tumor cells of diverse histogenesis, cell-cycle position and differentiation
    Bartkova, J; Zemanova, M; Bartek, J
  • Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets
    Walker, GJ; Flores, JF; Glendening, JM; Lin, AH; Markl, ID; Fountain, JW
  • Senescence-associated oxidative DNA damage promotes the generation of neoplastic cells
    Gosselin, K; Martien, S; Pourtier, A
  • Cancer, aging and cellular senescence
    Campisi, J
  • Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics
    Kerr, JFR; Wyllie, AH; Currie, AR
  • How death shapes life during development
    Baehrecke, EH
  • Programmed cell death in animal development and disease
    Fuchs, Y; Steller, H
  • Apoptosis in cancer: from pathogenesis to treatment
    Wong, RSY
  • p53: structure, function and therapeutic applications
    Bai, L; Zhu, WG
  • p53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation
    Avery-Kiejda, KA; Bowden, NA; Croft, AJ
  • Cell cycle checkpoints, genetic instability and cancer
    Weinert, T; Lydall, D
  • Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice
    Liu, G; Parant, JM; Lang, G
  • Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP
    Lu, M; Breyssens, H; Salter, V
  • Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53
    Mercer, WE; Shields, MT; Amin, M; Sauve, GJ; Appella, E; Romano, JW; Ullrich, SJ
  • The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
    Scheffner, M; Werness, BA; Huibregtse, JM; Levine, AJ; Howley, PM
  • Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
    Serrano, M; Lin, AW; McCurrach, ME; Beach, D; Lowe, SW
  • Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line
    Shaw, P; Bovey, R; Tardy, S; Sahli, R; Sordat, B; Costa, J
  • Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
    Yonish-Rouach, E; Resnitzky, D; Lotem, J; Sachs, L; Kimchi, A; Oren, M
  • Genetic instability and Darwinian selection in tumours
    Cahill, DP; Kinzler, KW; Vogelstein, B; Lengauer, C
  • Structure and function of telomeres
    Blackburn, EH
  • Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins
    Martínez, P; Blasco, MA
  • The RNA component of human telomerase
    Feng, J; Funk, WD; Wang, SS
  • Telomerase catalytic subunit homologs from fission yeast and human
    Nakamura, TM; Morin, GB; Chapman, KB
  • Telomere dynamics and telomerase activity in in vitro immortalised human cells
    Bryan, TM; Reddel, RR
  • Telomerase activity in normal and malignant hematopoietic cells
    Broccoli, D; Young, JW; Lange, T
  • Direct activation of TERT transcription by c-MYC
    Wu, KJ; Grandori, C; Amacker, M
  • A survey of telomerase activity in human cancer
    Shay, JW; Bacchetti, S
  • Telomere elongation in immortal human cells without detectable telomerase activity
    Bryan, TM; Englezou, A; Gupta, J; Bacchetti, S
  • Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer
    Hu, J; Hwang, SS; Liesa, M
  • Poly (ADP-ribose) polymerase: molecular biological aspects
    Murcia, G; Menissier-de Murcia, J; Schreiber, V
  • Involvement of poly (ADPribose) polymerase in base excision repair
    Dantzer, F; Schreiber, V; Niedergang, C
  • Stereo specific PARP trapping by BMN 673 and comparison with olaparib and rucaparib
    Murai, J; Huang, SY; Renaud, A
  • Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
    Fong, PC; Boss, DS; Yap, TA
  • Mechanisms of resistance to therapies targeting BRCA-mutant cancers
    Lord, CJ; Ashworth, A
  • Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
    Bouwman, P; Jonkers, J
  • APC restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer
    Dow, LE; O’Rourke, KP; Simon, J; Tschaharganeh, DF; Es, JH; Clevers, H; Lowe, SW
  • Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence
    Larsson, LG
  • DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
    Bartkova, J; Horejsí, Z; Koed, K
  • BRAFE600-associated senescence-like cell cycle arrest of human naevi
    Michaloglou, C; Vredeveld, LC; Soengas, MS
  • Four faces of cellular senescence
    Rodier, F; Campisi, J
  • The hallmarks of cancer
    Hanahan, D; Weinberg, RA
  • PRAK is essential for ras-induced senescence and tumor suppression
    Sun, P; Yoshizuka, N; New, L; Moser, BA; Li, Y; Liao, R
  • Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence
    Lin, HK; Chen, Z; Wang, G
  • Roles and mechanisms of cellular senescence in regulation of tissue homeostasis
    Ohtani, N; Hara, E
  • Cancer immunotherapy comes of age
    Topalian, SL; Weiner, GJ; Pardoll, DM
  • Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines
    Butt, AQ; Mills, KHG
  • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    Topalian, SL; Hodi, FS; Brahmer, JR
  • Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
    Topalian, SL; Sznol, M; Mcdermott, DF
  • Safety and tumor responses with lambrolizumab (anti- PD-1) in melanoma
    Hamid, O; Robert, C; Daud, A
  • PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma
    Ansell, SM; Lesokhin, AM; Borrello, I
  • Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
    Moreno, BH; Ribas, A
  • Therapeutic uses of anti-PD-1 and anti-PD-L1 Antibodies
    Philips, GK; Atkins, M
  • Targeting the immune system in cancer
    Chaudhuri, D; Suriano, R; Mittelman, A; Tiwari, RK
  • Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy
    Baxevanis, CN; Perez, SA; Papamichail, M
  • New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies
    Azijli, K; Stelloo, E; Peters, GJ; Eertwegh, AJ
  • PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
    Okazaki, T; Okazaki, IM; Wang, J
  • Opportunities and challenges in the development of experimental drug combinations for cancer
    Humphrey, R; Brockway-Lunardi, L; Bonk, D